# LIST OF CONTENTS

**TITLE**

**ABSTRACT**

**ABSTRAK**

**ACKNOWLEDGEMENTS**

**LIST OF CONTENTS**

**LIST OF TABLES**

**LIST OF FIGURES**

**LIST OF APPENDICES**

**LIST OF ABBREVIATIONS**

## CHAPTER 1: INTRODUCTION

1.1 General Introduction

1.2 Ethnic Group of Sarawak

1.3 Epidemiology of NPC

1.4 Classification of NPC

1.5 Aetiology Factors of NPC
   1.5.1 Genetic factors
   1.5.2 Environmental factors

1.6 Epstein-Barr Virus

1.7 EBV Structure

1.8 EBV Genome

1.9 EBV Infection
   1.9.1 Latent infection
   1.9.2 Lytic infection

1.10 EBV Antigens
   1.10.1 Viral capsid antigen (VCA)
   1.10.2 Early antigen (EA)
   1.10.3 BHRF1 protein

1.11 EBV Serology in NPC

1.12 Epitope Mapping Using Synthetic Peptides
   1.12.1 Multipin peptide synthesis

1.13 Objectives of This Study

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1</td>
<td>1</td>
</tr>
<tr>
<td>1.2</td>
<td>4</td>
</tr>
<tr>
<td>1.3</td>
<td>4</td>
</tr>
<tr>
<td>1.4</td>
<td>6</td>
</tr>
<tr>
<td>1.5</td>
<td>7</td>
</tr>
<tr>
<td>1.5.1</td>
<td>7</td>
</tr>
<tr>
<td>1.5.2</td>
<td>9</td>
</tr>
<tr>
<td>1.6</td>
<td>11</td>
</tr>
<tr>
<td>1.7</td>
<td>13</td>
</tr>
<tr>
<td>1.8</td>
<td>14</td>
</tr>
<tr>
<td>1.9</td>
<td>16</td>
</tr>
<tr>
<td>1.9.1</td>
<td>16</td>
</tr>
<tr>
<td>1.9.2</td>
<td>19</td>
</tr>
<tr>
<td>1.10</td>
<td>20</td>
</tr>
<tr>
<td>1.10.1</td>
<td>20</td>
</tr>
<tr>
<td>1.10.2</td>
<td>21</td>
</tr>
<tr>
<td>1.10.3</td>
<td>23</td>
</tr>
<tr>
<td>1.11</td>
<td>24</td>
</tr>
<tr>
<td>1.12</td>
<td>29</td>
</tr>
<tr>
<td>1.12.1</td>
<td>32</td>
</tr>
<tr>
<td>1.13</td>
<td>33</td>
</tr>
</tbody>
</table>
CHAPTER 2: MATERIALS AND METHODS

2.1 Epstein-Barr Virus (EBV) Serology Assay

2.1.1 Cell lines

2.1.2 Solutions

2.1.2.1 Culture medium

2.1.2.2 Phosphate buffered saline (PBS)

2.1.2.3 Sodium butyrate (NBA)

2.1.2.4 12-O-tetradecanoyl phorbol 13-acetate (TPA)

2.1.3 Reviving and culturing of cells

2.1.4 Cell count and viability test

2.1.5 Induction of cells

2.1.6 Harvesting of induced cells

2.1.7 Serum samples

2.1.8 Immunofluorescence assay (IFA) for anti-EBV antibodies

2.2 Multipin Peptide Synthesis

2.2.1 Multipin peptide synthesis kit

2.2.2 Synthesis procedures

2.3 Multipin Enzyme-Linked Immunosorbent Assay (ELISA)

2.3.1 Solutions

2.3.1.1 Phosphate buffered saline (PBS)

2.3.1.2 Pre-coat buffer

2.3.1.3 Conjugate diluent

2.3.1.4 Substrate buffer solution

2.3.1.5 O-phenylenediamine (OPD) substrate solution

2.3.1.6 Disruption buffer

2.3.2 Serum samples

2.3.3 Multipin enzyme-linked immunosorbent assay (ELISA)

CHAPTER 3: RESULTS

3.1 Serum Samples

3.2 Immunofluorescence Assay (IFA) for Anti-EBV Antibodies

3.3 Titres and Distribution of Anti-EBV Antibodies

3.3.1 Anti-EBV antibodies with respect to sex

3.3.2 Anti-EBV antibodies with respect to ethnic groups

3.3.3 Anti-EBV antibodies with respect to age groups

3.4 Determination of Cut-off Titres and Geometric Mean Titres

3.5 Comparison of Anti-EBV Serological Markers

3.6 Anti-EBV Serological Profiles

3.7 Multipin Peptide Synthesis of EBV BHRF1 Protein

3.7.1 Multipin BHRF1 peptide ELISA

3.7.2 IgA linear epitope of BHRF1 in NPC
CHAPTER 4: DISCUSSION

4.1 Incidences of NPC in Sarawak

4.2 Detection of Anti-Epstein-Barr Virus Antibodies
   4.2.1 Anti-EBV antibodies in NPC patients with respect
to sex, ethnic groups and age
   4.2.2 Sensitivity and specificity of anti-EBV antibody assays
   4.2.3 Evaluation of anti-EBV antibody profile

4.3 Epitope Analysis of EBV BHRF1 Protein

CHAPTER 5: CONCLUSION

REFERENCES

APPENDICES
<table>
<thead>
<tr>
<th>Table</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table 1.1</td>
<td>Population estimate by ethnic group.</td>
<td>4</td>
</tr>
<tr>
<td>Table 1.2</td>
<td>EBV-specific antigens and immunological response in patients with EBV-associated disease (Tam &amp; Murray, 1990; Tam, 1991).</td>
<td>24</td>
</tr>
<tr>
<td>Table 1.3</td>
<td>Sensitivity and specificity of IgA/VCA in the diagnosis of NPC.</td>
<td>25</td>
</tr>
<tr>
<td>Table 1.4</td>
<td>Potential individual polypeptides of the antigen complexes of EBV for the diagnosis of NPC.</td>
<td>28</td>
</tr>
<tr>
<td>Table 3.1</td>
<td>Distribution of sera by sex.</td>
<td>49</td>
</tr>
<tr>
<td>Table 3.2</td>
<td>Distribution of sera by ethnic group.</td>
<td>50</td>
</tr>
<tr>
<td>Table 3.3</td>
<td>Distribution of sera by age group.</td>
<td>50</td>
</tr>
<tr>
<td>Table 3.4</td>
<td>Titres of IgA/VCA in NPC and non-NPC controls.</td>
<td>53</td>
</tr>
<tr>
<td>Table 3.5</td>
<td>Titres of IgG/VCA in NPC and non-NPC controls.</td>
<td>54</td>
</tr>
<tr>
<td>Table 3.6</td>
<td>Titres of IgA/EA in NPC and non-NPC controls.</td>
<td>55</td>
</tr>
<tr>
<td>Table 3.7</td>
<td>Titres of IgG/EA in NPC and non-NPC controls.</td>
<td>56</td>
</tr>
<tr>
<td>Table 3.8</td>
<td>GMTs and significance values between NPC and non-NPC controls.</td>
<td>57</td>
</tr>
<tr>
<td>Table 3.9</td>
<td>Geometric mean titre (GMT) and p value of anti-EBV antibodies in NPC patients with respect to sex.</td>
<td>58</td>
</tr>
<tr>
<td>Table 3.10</td>
<td>Geometric mean titre (GMT) of anti-EBV antibodies in NPC patients with respect to ethnic groups.</td>
<td>60</td>
</tr>
<tr>
<td>Table 3.11</td>
<td>Geometric mean titre (GMT) of anti-EBV antibodies in NPC patients with respect to age groups.</td>
<td>63</td>
</tr>
<tr>
<td>Table 3.12</td>
<td>Comparison of sensitivity and specificity of anti-EBV antibodies at different cut-off titres.</td>
<td>65</td>
</tr>
<tr>
<td>Table 3.13</td>
<td>Percentage of positivity and GMT of EBV serological markers in NPC and non-NPC controls.</td>
<td>66</td>
</tr>
</tbody>
</table>
Table 3.14 : Anti-EBV serological profiles of NPC samples. 71
Table 3.15 : Sensitivity and specificity of different combinations of 2 anti-EBV antibodies 71
Table 3.16 : Major EBV BHRF1 peptides reactive with IgA in NPC sera. 77
Table 4.1 : Various cut-off titre of EBV measured by IFA. 83
Table 4.2 : Percentage of negative IgA/VCA titre in NPC confirmed patients. 86
<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Figure 1.1 : The various states in Malaysia.</td>
<td>3</td>
</tr>
<tr>
<td>Figure 1.2 : Herpesvirus structure and morphology (Ackermann &amp; Berthiaume, 1995).</td>
<td>12</td>
</tr>
<tr>
<td>Figure 1.3 : The structure of the Epstein-Barr virus genome with selected genes expressed during lytic and latency cycle (Cohen, 1997).</td>
<td>15</td>
</tr>
<tr>
<td>Figure 1.4 : Solid phase peptide synthesis: a cyclical, three-step process.</td>
<td>31</td>
</tr>
<tr>
<td>Figure 2.1 : The amino acids residues of BHRF1 protein. The alphabets represent single letter abbreviation for amino acids.</td>
<td>39</td>
</tr>
<tr>
<td>Figure 2.2 : The Multipin Peptide Synthesis Kit (Chiron, Australia).</td>
<td>40</td>
</tr>
<tr>
<td>Figure 2.3 : The numbering system of reaction tray.</td>
<td>41</td>
</tr>
<tr>
<td>Figure 3.1 : Positive immunofluorescence assay (IFA) staining of IgA/EA with Raji cells (Magnification X200).</td>
<td>52</td>
</tr>
<tr>
<td>Figure 3.2 : Negative immunofluorescence assay (IFA) staining of IgA/EA with Raji cells (Magnification X200).</td>
<td>52</td>
</tr>
<tr>
<td>Figure 3.3 : Distribution of IgA/VCA titres in NPC and non-NPC controls.</td>
<td>53</td>
</tr>
<tr>
<td>Figure 3.4 : Distribution of IgG/VCA titres in NPC and non-NPC controls.</td>
<td>54</td>
</tr>
<tr>
<td>Figure 3.5 : Distribution of IgA/EA titres in NPC and non-NPC controls.</td>
<td>55</td>
</tr>
<tr>
<td>Figure 3.6 : Distribution of IgG/EA titres in NPC and non-NPC controls.</td>
<td>56</td>
</tr>
<tr>
<td>Figure 3.7 : GMT of anti-EBV antibodies by sex.</td>
<td>58</td>
</tr>
<tr>
<td>Figure 3.8 : GMT of IgA/VCA by ethnic group.</td>
<td>60</td>
</tr>
<tr>
<td>Figure 3.9 : GMT of IgG/VCA by ethnic group.</td>
<td>61</td>
</tr>
</tbody>
</table>
Figure 3.10: GMT of IgA/EA by ethnic group. 61
Figure 3.11: GMT of IgG/EA by ethnic group. 61
Figure 3.12: GMT of IgA/VCA by age group. 63
Figure 3.13: GMT of IgG/VCA by age group. 64
Figure 3.14: GMT of IgA/EA by age group. 64
Figure 3.15: GMT of IgG/EA by age group. 64
Figure 3.16: IgG/VCA and IgA/VCA titres in NPC samples. 67
Figure 3.17: IgG/VCA and IgA/EA titres in NPC samples. 68
Figure 3.18: IgG/VCA and IgG/EA titres in NPC samples. 69
Figure 3.19: Comparison of the mean absorbance between the conjugate test and 5 NPC sera. 72
Figure 3.20: BHRF1 peptide reactivity profile for 5 NPC sera and 1 control serum. 74
Figure 3.21: BHRF1 peptide reactivity profile of IgA antibodies in 3 NPC sera. 75
Figure 3.22: BHRF1 peptide reactivity profile of IgA antibodies in 2 NPC sera and 1 control serum. 76
Figure 3.23: The specific IgA antibody binding to BHRF1 peptides in NPC sera. 78